5784-45-2

Basic information

• Product Name: 1-CHLOROPHTHALAZINE
• Synonyms: 1-Chlorophthalazine;NSC 71104;1-Chlorophthalazine Discontinued See C379660;Hydralazine IMpurity 02;Hydralazine Chloro IMpurity;1-Chloro-2,3-benzodiazine;Phthalazine, 1-chloro-
• CAS NO: 5784-45-2
• Molecular Formula: C₈H₅ClN₂
• Molecular Weight: 164.59
• Product Categories: Aromatics Compounds;Aromatics
• Mol File: 5784-45-2.mol
• Article Data: 13

Chemical Properties

• Melting Point: 109-112°C
• Boiling Point: 364.3 °C at 760 mmHg
• Flash Point: 205.6 °C
• Appearance: Brown Solid
• Density: 1.349g/cm³
• Vapor Pressure: 4.43E-07mmHg at 25°C
• Refractive Index: 1.643
• Storage Temp.: -20?C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 1.74±0.10(Predicted)
• Water Solubility: Insoluble in water. Soluble in dichloromethane, ethanol and methanol.
• Sensitive: Moisture Sensitive
• Stability: Moisture Sensitive
• CAS DataBase Reference: 1-CHLOROPHTHALAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-CHLOROPHTHALAZINE(5784-45-2)
• EPA Substance Registry System: 1-CHLOROPHTHALAZINE(5784-45-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 5784-45-2(Hazardous Substances Data)

Usage

Description

1-Chlorophthalazine is a chemical compound with the molecular formula C8H5ClN2 and is classified as a brown solid. It is primarily utilized in the pharmaceutical industry as an intermediate for the synthesis of various drugs and is also used in the production of medical isotopes.

Uses

Used in Pharmaceutical Industry:
1-Chlorophthalazine is used as a pharmaceutical intermediate for the synthesis of various drugs. Its chemical structure allows it to be a key component in the development of new medications, contributing to the advancement of pharmaceutical research and drug discovery.
Used in Medical Isotopes Production:
1-Chlorophthalazine is also employed in the production of medical isotopes, which are essential for diagnostic and therapeutic applications in the field of nuclear medicine. These isotopes play a crucial role in the detection and treatment of various diseases, including cancer, cardiovascular conditions, and neurological disorders.

InChI:InChI=1/C10H11N3/c1-7-4-2-3-5-8(7)9-6-10(11)13-12-9/h2-6H,1H3,(H3,11,12,13)

Upstream product

• 119-39-1 phthalazone 
• 10025-87-3 trichlorophosphate 
• 119-67-5 o-carboxybenzaldehyde 
• 253-52-1 PHTHALAZINE 
• 119-39-1 1-hydroxy-2,3-benzodiazine 

Downstream Products

• 24953-56-8 1-methoxyphthalazine 
• 90915-02-9 1-ethoxyphthalazine 
• 24953-63-7 α-Phenyl-1-phthalazinacetonitril 
• 109127-95-9 sulfanilic acid phthalazin-1-ylamide 
• 109516-21-4 toluene-4-sulfonic acid-(N'-phthalazin-1-yl-hydrazide); hydrochloride 
• 100537-30-2 1-Phenoxy-phthalazin 
• 253-52-1 PHTHALAZINE 
• 496-12-8 isoindoline 
• 19064-69-8 phthalazin-1-ylamine 
• 119-39-1 phthalazone 
• 85236-43-7 1-(4-hydroxyanilino)phthalazine 
• 13969-11-4 10-Oxo-3,4-benzo-dihydropyridazino-chinazolin 
• 7134-95-4 1'H-1,2'-biphthalazinyl-1'-one 

Relevant articles and documents

Design and Synthesis of 1,2-Bis(hydroxymethyl)pyrrolo[2,1- a]phthalazine Hybrids as Potent Anticancer Agents that Inhibit Angiogenesis and Induce DNA Interstrand Cross-links

Hybrid molecules are composed of two pharmacophores with different biological activities. Here, we conjugated phthalazine moieties (antiangiogenetic pharmacophore) and bis(hydroxymethyl)pyrrole moieties (DNA cross-linking agent) to form a series of bis(hydroxymethyl)pyrrolo[2,1-a]phthalazine hybrids. These conjugates were cytotoxic to a variety of cancer cell lines by inducing DNA damage, arresting cell cycle progression at the G2/M phase, triggering apoptosis, and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2) in endothelial cells. Among them, compound 29d encapsulated in a liposomal formulation (e.g., 29dL) significantly suppressed the growth of small-cell lung cancer cell (H526) xenografts in mice. Based on immunohistochemical staining, the tumor xenografts in mice treated with 29dL showed time-dependent decreases in the intensity of CD31, a marker of blood vessels, whereas the intensity of γ-H2AX, a marker of DNA damage, increased. The present data revealed that the conjugation of antiangiogenic and DNA-damaging agents can generate potential hybrid agents for cancer treatment.

BIS(HYDROXYMETHYL) PYRROLOPHTHALAZINE HYBRIDS, PREPARATION METHODS AND USES THEREOF

Disclosed herein are novel bifunctional compounds and their uses for the treatment and/or prophylaxis of cancers. The bifunctional compound disclosed herein has the structure of formula (I).

Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity

Efforts to develop new antitumor agents are now directed towards multitarget therapies that are believed to have high potency and low tendency to resistance compared to conventional drugs. Herein, we highlighted the synthesis and antitumor activity of five series of phthalazine-based compounds featuring a variety of bioactive chemical fragments at position 1 of the phthalazine nucleus. The antitumor activity of the target compounds was performed against fourteen cancer cell lines where all compounds were active in the nanomolar level. In addition, the mechanism of action of the target compounds was investigated through an enzymatic inhibitory assay against VEGFR-2 and EGFR kinases, revealing potent and preferential activity toward VEGFR-2. Binding mode of the most active compounds was studied using docking experiment.